The Technical Analyst
Select Language :
Monte Rosa Therapeutics, [GLUE]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Monte Rosa Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Monte Rosa Therapeutics, is listed at the  Exchange

6.83% $7.04

America/New_York / 27 mar 2024 @ 16:00


Monte Rosa Therapeutics,: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 353.08 mill
EPS: -2.63
P/E: -2.68
Earnings Date: May 09, 2024
SharesOutstanding: 50.15 mill
Avg Daily Volume: 0.155 mill
RATING 2024-03-27
B
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Sell
Return On Asset: Sell
DE: Buy
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -2.68 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.46x
Company: PE -2.68 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$1.597
(-77.32%) $-5.44
Date: 2024-03-28
Expected Trading Range (DAY)

$ 6.50 - 7.62

( +/- 7.99%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-01-02 Warmuth Markus Buy 346 000 Stock Option (Right to Buy)
2024-01-02 Wallace Owen B. Buy 119 000 Stock Option (Right to Buy)
2024-01-02 Jones Jullian G Buy 79 000 Stock Option (Right to Buy)
2024-01-02 Janku Filip Buy 121 000 Stock Option (Right to Buy)
2024-01-02 Nickson Philip Buy 109 000 Stock Option (Right to Buy)
INSIDER POWER
92.76
Last 98 transactions
Buy: 57 206 836 | Sell: 164 598 288

Forecast: 16:00 - $7.06

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $7.06
Forecast 2: 16:00 - $7.06
Forecast 3: 16:00 - $7.06
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $7.04 (6.83% )
Volume 0.147 mill
Avg. Vol. 0.155 mill
% of Avg. Vol 94.54 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Monte Rosa Therapeutics, Inc.

Last 12 Months

Last 12 months chart data with high, low, open and close for Monte Rosa Therapeutics, Inc.

RSI

Intraday RSI14 chart for Monte Rosa Therapeutics, Inc.

Last 10 Buy & Sell Signals For GLUE

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:03sell$4.74N/AActive
Profile picture for
            Monte Rosa Therapeutics, Inc.

GLUE

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Last 10 Buy Signals

Date Signal @
PENDLEUSDMar 28 - 07:284.12
KCSUSDMar 28 - 07:19$12.09
DIGGUSDMar 28 - 07:19914.30
ETHXUSDMar 28 - 07:183 584.83
CTXUSDMar 28 - 07:194.55
TETUSDMar 28 - 07:1328.60
RUNEUSDMar 28 - 07:15$9.38
HTUSDMar 28 - 07:14$0.850
^AEXMar 28 - 07:00PTS881.83
PROPCUSDMar 28 - 07:084.91

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.